A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2021
This article has no abstract
Epistemonikos ID: 364a9a2a1a25080efb254cf49cb150a6cfd697b6
First added on: Apr 11, 2025